D A George1, K M Sarraf, H Nwaboku. 1. Department of Trauma and Orthopaedics, Barnet Hospital, Wellhouse Lane, Barnet, EN5 3DJ, UK, davidgeorge@doctors.org.uk.
Abstract
INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin. It has been shown to reduce blood loss in trauma and other haemorrhagic conditions and has recently been utilised in elective orthopaedic surgery. There are various methods of administering TXA described in the literature. METHODS: This retrospective cohort study reviews the effects of a single perioperative 1 g intravenous bolus on patients undergoing primary hip and knee arthroplasty and its effect on operative blood loss. After excluding patients who did not fulfil our inclusion criteria, a total of 110 patients were included in this study. Fifty underwent primary hip arthroplasty (30 treated with TXA; 60.0 %), and 60 underwent primary knee arthroplasty (29 treated with TXA; 48.3 %). The main outcome measure was red cell volume and total blood loss, and secondary measures were needed for blood transfusions, presence of thromboembolic events, and length of hospital stay. RESULTS: Both cohorts who received TXA showed a reduction in immediate postoperative red cell volume loss and total blood loss (p < 0.01). There was no association with the administration of TXA and the rate of postoperative blood transfusions (hip p = 0.36, knee p = 0.13), incidence of symptomatic deep vein thrombosis (hip p = 0.36, knee p = 0.31), or postoperative hospital length of stay (hip p = 0.70, knee p = 0.68). CONCLUSION: This study demonstrates that a single perioperative bolus of intravenous TXA may significantly reduce operative blood loss in both primary total hip and knee arthroplasty in a cost-effective manner, in combination with meticulous perioperative haemostasis.
INTRODUCTION:Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin. It has been shown to reduce blood loss in trauma and other haemorrhagic conditions and has recently been utilised in elective orthopaedic surgery. There are various methods of administering TXA described in the literature. METHODS: This retrospective cohort study reviews the effects of a single perioperative 1 g intravenous bolus on patients undergoing primary hip and knee arthroplasty and its effect on operative blood loss. After excluding patients who did not fulfil our inclusion criteria, a total of 110 patients were included in this study. Fifty underwent primary hip arthroplasty (30 treated with TXA; 60.0 %), and 60 underwent primary knee arthroplasty (29 treated with TXA; 48.3 %). The main outcome measure was red cell volume and total blood loss, and secondary measures were needed for blood transfusions, presence of thromboembolic events, and length of hospital stay. RESULTS: Both cohorts who received TXA showed a reduction in immediate postoperative red cell volume loss and total blood loss (p < 0.01). There was no association with the administration of TXA and the rate of postoperative blood transfusions (hip p = 0.36, knee p = 0.13), incidence of symptomatic deep vein thrombosis (hip p = 0.36, knee p = 0.31), or postoperative hospital length of stay (hip p = 0.70, knee p = 0.68). CONCLUSION: This study demonstrates that a single perioperative bolus of intravenous TXA may significantly reduce operative blood loss in both primary total hip and knee arthroplasty in a cost-effective manner, in combination with meticulous perioperative haemostasis.
Authors: Jean Wong; Amir Abrishami; Hossam El Beheiry; Nizar N Mahomed; J Roderick Davey; Rajiv Gandhi; Khalid A Syed; Syed Muhammad Ovais Hasan; Yoshani De Silva; Frances Chung Journal: J Bone Joint Surg Am Date: 2010-11-03 Impact factor: 5.284
Authors: Haleema Shakur; Ian Roberts; Raúl Bautista; José Caballero; Tim Coats; Yashbir Dewan; Hesham El-Sayed; Tamar Gogichaishvili; Sanjay Gupta; Jorge Herrera; Beverley Hunt; Pius Iribhogbe; Mario Izurieta; Hussein Khamis; Edward Komolafe; María-Acelia Marrero; Jorge Mejía-Mantilla; Jaime Miranda; Carlos Morales; Oluwole Olaomi; Fatos Olldashi; Pablo Perel; Richard Peto; P V Ramana; R R Ravi; Surakrant Yutthakasemsunt Journal: Lancet Date: 2010-06-14 Impact factor: 79.321
Authors: Fiona E Ralley; Donna Berta; Valerie Binns; James Howard; Douglas D R Naudie Journal: Clin Orthop Relat Res Date: 2010-01-09 Impact factor: 4.176
Authors: Panayiotis K Karampinas; Panayiotis D Megaloikonomos; Kalliopi Lampropoulou-Adamidou; Eleftherios G Papadelis; Andreas F Mavrogenis; John A Vlamis; Spyros G Pneumaticos Journal: Eur J Orthop Surg Traumatol Date: 2018-09-17
Authors: Andrew G Golz; Heather K Yee; Benjamin J Davis; William H Adams; Nicholas M Brown Journal: J Am Acad Orthop Surg Date: 2021-06-01 Impact factor: 4.000
Authors: Elizabeth Bishop Gausden; Matthew R Garner; Stephen J Warner; Ashley Levack; Andrew M Nellestein; Tiffany Tedore; Eva Flores; Dean G Lorich Journal: BMJ Open Date: 2016-06-21 Impact factor: 2.692
Authors: Mehmet Ali Talmaç; Mehmet Akif Görgel; Sema Ertan Birsel; Mehmet Mesut Sönmez; Hacı Mustafa Özdemir Journal: Sisli Etfal Hastan Tip Bul Date: 2019-06-21